These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 30425352)
1. Long-term treatment with the PARP inhibitor niraparib does not increase the mutation load in cell line models and tumour xenografts. Póti Á; Berta K; Xiao Y; Pipek O; Klus GT; Ried T; Csabai I; Wilcoxen K; Mikule K; Szallasi Z; Szüts D Br J Cancer; 2018 Nov; 119(11):1392-1400. PubMed ID: 30425352 [TBL] [Abstract][Full Text] [Related]
2. In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma. AlHilli MM; Becker MA; Weroha SJ; Flatten KS; Hurley RM; Harrell MI; Oberg AL; Maurer MJ; Hawthorne KM; Hou X; Harrington SC; McKinstry S; Meng XW; Wilcoxen KM; Kalli KR; Swisher EM; Kaufmann SH; Haluska P Gynecol Oncol; 2016 Nov; 143(2):379-388. PubMed ID: 27614696 [TBL] [Abstract][Full Text] [Related]
3. Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas. Li H; Tu J; Zhao Z; Chen L; Qu Y; Li H; Yao H; Wang X; Lee DF; Shen J; Wen L; Huang G; Xie X Theranostics; 2020; 10(21):9477-9494. PubMed ID: 32863940 [No Abstract] [Full Text] [Related]
4. Niraparib for the treatment of ovarian cancer. Kanjanapan Y; Lheureux S; Oza AM Expert Opin Pharmacother; 2017 Apr; 18(6):631-640. PubMed ID: 28299955 [TBL] [Abstract][Full Text] [Related]
5. Niraparib Slows Ovarian Cancer Progression. Cancer Discov; 2016 Dec; 6(12):OF2. PubMed ID: 27810860 [TBL] [Abstract][Full Text] [Related]
6. The role of niraparib for the treatment of ovarian cancer. Ethier JL; Lheureux S; Oza AM Future Oncol; 2018 Oct; 14(25):2565-2577. PubMed ID: 29856239 [TBL] [Abstract][Full Text] [Related]
8. Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US. Wu L; Zhong L J Med Econ; 2019 Feb; 22(2):187-195. PubMed ID: 30522378 [TBL] [Abstract][Full Text] [Related]
9. Niraparib: A Review in Ovarian Cancer. Heo YA; Duggan ST Target Oncol; 2018 Aug; 13(4):533-539. PubMed ID: 30073633 [TBL] [Abstract][Full Text] [Related]
10. Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination. Jones P; Wilcoxen K; Rowley M; Toniatti C J Med Chem; 2015 Apr; 58(8):3302-14. PubMed ID: 25761096 [TBL] [Abstract][Full Text] [Related]
11. Niraparib in the treatment of previously treated advanced ovarian, fallopian tube or primary peritoneal cancer. Rimel BJ; Dockery L; Randall LM; Moore K Future Oncol; 2020 Nov; 16(33):2701-2711. PubMed ID: 32880196 [TBL] [Abstract][Full Text] [Related]
16. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy]. Schreiber V; Illuzzi G; Héberlé E; Dantzer F Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693 [TBL] [Abstract][Full Text] [Related]
17. Niraparib: First Global Approval. Scott LJ Drugs; 2017 Jun; 77(9):1029-1034. PubMed ID: 28474297 [TBL] [Abstract][Full Text] [Related]
18. PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review. Cook SA; Tinker AV BioDrugs; 2019 Jun; 33(3):255-273. PubMed ID: 30895466 [TBL] [Abstract][Full Text] [Related]
19. The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality. Papadimitriou M; Mountzios G; Papadimitriou CA Cancer Treat Rev; 2018 Jun; 67():34-44. PubMed ID: 29753961 [TBL] [Abstract][Full Text] [Related]
20. Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery. Jiang J; Lu Y; Li Z; Li L; Niu D; Xu W; Liu J; Fu L; Zhou Z; Gu Y; Xia F Invest New Drugs; 2017 Jun; 35(3):251-259. PubMed ID: 28111726 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]